Article
ALK1-BMPRII agonism by clustering bispecific antibodies treats hereditary hemorrhagic telangiectasia
2025-08-14
Abstract excerpt
Hereditary hemorrhagic telangiectasia (HHT) is characterized by arteriovenous malformations (AVMs) and severe bleeding caused by loss-of-function mutations in the ALK1 receptor pathway. We developed clustering agonist bispecific antibodies (BsAbs) targeting ALK1 and its activating partner, the Ser/Thr receptor kinase BMPRII. These BsAbs induced ALK1-BMPRII proximity association, stimulated the downstream Smad1/5/8...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 863b9b72-2c5c-5534-ac90-1d67b5706cf8
- DOI
- 10.1101/2025.08.13.670104
